CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

Company Overview

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues. These bioinks serve as scaffolds to support cell growth and tissue formation, targeting indications such as cartilage repair, orthopedic implants and breast reconstruction. The company’s preclinical pipeline extends into areas like tendon and ligament engineering, leveraging its collagen platform to address unmet needs in regenerative therapy.

Founded in 2009 and headquartered in Rehovot, Israel, CollPlant maintains operations in the United States with offices in Bridgewater, New Jersey. The company has secured CE Mark approvals for several products in Europe and is pursuing additional regulatory clearances worldwide. Through strategic collaborations and licensing agreements, CollPlant aims to expand its global footprint across North America, Europe and Asia, partnering with device manufacturers and research institutions to accelerate product development.

Under the leadership of President and Chief Executive Officer Yehiel Tal, CollPlant’s management team combines expertise in biotechnology, medical devices and pharmaceutical development. The company continues to invest in research, manufacturing capacity and strategic partnerships to advance its vision of providing sustainable, high-quality collagen solutions for the regenerative medicine market.

Key Stats

• Today's Range: $0.40 to $0.43
• 50-Day Range: $0.29 to $0.75
• 52-Week Range: $0.27 to $4.98
• Volume: 45,851 shs
• Average Volume: 170,688 shs
• Market Capitalization: $5.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Hold

CollPlant Biotechnologies Stock Analysis - MarketRank™

CollPlant Biotechnologies scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

CollPlant Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

CollPlant Biotechnologies has a consensus price target of $11.50, representing about 2,774.3% upside from its current price of $0.40.

Amount of Analyst Coverage

CollPlant Biotechnologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CollPlant Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CollPlant Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CollPlant Biotechnologies has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CLGN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CollPlant Biotechnologies does not currently pay a dividend.

Dividend Growth

CollPlant Biotechnologies does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for CLGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.60% of the stock of CollPlant Biotechnologies is held by insiders.

Percentage Held by Institutions

21.69% of the stock of CollPlant Biotechnologies is held by institutions.

CLGN Stock Analysis - Frequently Asked Questions

How have CLGN shares performed this year?

CollPlant Biotechnologies' stock was trading at $1.40 at the start of the year. Since then, CLGN stock has decreased by 71.4% and is now trading at $0.4001.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN) announced its quarterly earnings data on Wednesday, November, 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by $0.65. The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $16.52 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 161.69% and a negative net margin of 353.70%.

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann served as the underwriter for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA).

Company Calendar

• Last Earnings: 11/26/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CLGN
• CIK: 1631487
• Web: www.collplant.com
• Phone: 972732325600
• Fax: 972-73-232-5602
• Employees: 70
• Year Founded: 1981

Price Target and Rating

• Average Price Target for CollPlant Biotechnologies: $11.50
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +2,774.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.49 million
• Net Margins: -353.70%
• Pretax Margin: -484.56%
• Return on Equity: -161.69%
• Return on Assets: -109.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.53
• Quick Ratio: 2.31

Sales & Book Value

• Annual Sales: $2.37 million
• Price / Sales: 2.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.48 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 14,410,000
• Free Float: 13,031,000
• Market Cap: $5.77 million
• Optionable: Optionable
• Beta: 1.47